Comparative Pharmacology
Head-to-head clinical analysis: MOTOFEN versus MOTOFEN HALF STRENGTH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOTOFEN versus MOTOFEN HALF STRENGTH.
MOTOFEN vs MOTOFEN HALF-STRENGTH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of diphenoxylate (opioid agonist) and atropine (anticholinergic). Diphenoxylate acts on μ-opioid receptors in the gut to slow peristalsis and reduce fluid secretion; atropine is added to discourage abuse by causing unpleasant anticholinergic effects at high doses.
Motofen Half-Strength contains difenoxin (an opioid agonist) and atropine (an anticholinergic). Difenoxin inhibits gastrointestinal motility by acting on mu-opioid receptors in the gut, reducing peristalsis. Atropine discourages abuse by producing unpleasant anticholinergic effects at supratherapeutic doses.
1 to 2 tablets orally every 6 hours as needed, not to exceed 8 tablets per day.
Adults: 1 tablet (diphenoxylate 1 mg + atropine 0.0125 mg) orally 4 times daily as needed for diarrhea, up to 8 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 20-24 hours; clinical context: once-daily dosing recommended
Terminal elimination half-life is 2-3 hours for diphenoxylate, 12-14 hours for atropine. Clinical context: Steady-state achieved within 1 day for diphenoxylate, 3 days for atropine.
Renal: ~60%; Fecal/Biliary: ~40%
Renal (50% as unchanged drug and conjugates), biliary/fecal (30% as metabolites), 20% unknown.
Category C
Category C
Antidiarrheal
Antidiarrheal